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Background. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract and are
diagnosed relatively seldom in pregnancy. Case. We describe a remarkable clinical course and long-term outcome, now nine
years after ﬁrst diagnosis, of a massive and metastatic, with a high malignancy grade GIST case, found in and treated from the
ﬁrst trimester of pregnancy onwards. Conclusion. GIST occurring during pregnancy is extremely rare. However, early diagnosis
is important for optimal management. The recent better understanding of oncogenesis, the use of immunohistochemistry for
diﬀerential diagnosis of GISTs, and the use of imatinib mesylate as the treatment of ﬁrst choice are—as shown in this case—
important for care of pregnant women with this type of malignancy.
Copyright © 2009 S. Scherjon et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the digestive tract [1]. They
most often occur in the stomach followed by the duodenum
[2]. The availability of therapeutic options for metastatic
GISTs [3] as well as the availability of reliable immuno-
histochemical staining methods has raised the reported
incidence to 12.7 per million inhabitants, as published in
aD u t c hn a t i o nw i d es u r v e y[ 4]. Given the age distribution
of occurrence, a diagnosis of GIST during pregnancy is
very uncommon [5, 6]. Those few cases reported however
were symptomatic and found in the second half of the
pregnancy, leading to an emergency caesarean section in one
case due to fetal distress during laparotomy [5]. In the case
report of Lanzafame both fetal and maternal outcome were
unfortunately not reported [6]. Here we report the clinical
course with long-term followup of a massive and metastatic
GIST found in the ﬁrst trimester of pregnancy.
2.CaseReport9Years
A 25-year-old woman in her ﬁrst pregnancy with an unre-
markable medical and family history was referred during the
ﬁrst trimester to the Department of Obstetrics because on
palpation the uterus was considered too large for her gesta-
tional age. She had no history of an irregular menstruation
cycle. At a gestational age of 10 3/7 weeks (June 2000) the
fundal height as estimated by external examination—at that
gestational age just palpable at the symphysis—was already
at the level of the umbilicus, comparable to a gestational
age of 24 weeks, while at ultrasound the crown rump length
was in accordance with the menstrual age. On routine ultra-
sound the uterus was found normal; the ovaries were not
visualized. Dorsal of the uterus a nonspeciﬁc mass of 10cm
× 7cm with both echodense and echolucent characteristics
was seen. A more detailed ultrasound, performed at the
Prenatal Diagnosis Unit making use of the highest quality
ultrasound technology, was repeated a week later. Findings
were similar as the week before. The mass dorsal of the
uterus was unchanged. Color Doppler Sonography showed
extensive vascularity within the mass. Clinically she had no
complaintsoranyothersymptoms.Onphysicalexamination
the fundus was palpated in accordance with gestational
age (11 3/7 weeks: 3cm above the symphysis), however
an irregular tumor, which could be palpated separate from
the uterus, stretched from the umbilicus to the pelvic
region could be delineated. Except for a slight-pregnancy2 Case Reports in Medicine
related increase in tumormarker Cancer-Antigen 125 (CA
125: 49nmol/L), other laboratory ﬁndings, including Car-
cinoEmbryonal Antigen (CEA) showed no abnormality. In
normal pregnancy an elevation of CA 125 serum levels is
found [7].
Because of the suspicion of an ovarian mass at a
gestational age of 15 weeks and 1 day, a laparoscopy was
performed. It was converted to laparotomy because of
suspicion of a malignancy originating from the left ovary.
However, at palpation and inspection the uterus and the
both ovaries were found normal. A tumor mass of more
than 20cm diameter was located behind the uterus. The
tumorwasattachedextensivelytothejejunum,theappendix,
the epiploic appendices and to the rectouterine pouch. The
tumor was resected en bloc with the appendix and a part of
the jejunum. As multiple small lesions were found on the
spleen at inspection, which were thought macroscopically
during the operation to be of possible metastatic origin,
a splenectomy was performed. Because of this ﬁnding the
procedure was considered nonradical.
Macroscopic Description of the Surgical Specimens. The large
tumor was divided in 2 fragments: measuring 17×16×5cm
and13×8×3.5cm,respectively.Bothfragmentshadasimilar
macroscopic morphology. The tumor had a yellow-gray,
irregular, coarse to nodular surface. Internally there were
multiplecystswithhemorrhageandcentralcalciﬁcation.The
second fragment included the appendix and a small part
of the coecum, which were surrounded by the tumor. The
spleen measured 9.5 × 8 × 5cm.Afewyellow-graynodules
were seen under the capsule. Internally, irregular yellow-gray
nodules were found throughout the entire spleen.
Microscopic Description. Spindle cells orderly organized in
fascicles separated by stroma were seen in both fragments
of the tumorous mass, in the jejunum and in the nodules
of the spleen. The cells had vague indistinct borders. The
nucleiwereroundovaltostretchedwithgranularchromatin.
Hyaline degeneration was located in the center of the
nodules. Macrophages with iron pigments were scattered
over the tissue. Mitotic ﬁgures were only found in the tumor
near the jejunum with a mitotic rate of 5/50HPF.
Immunohistochemistry showed tumor cells to be posi-
tive for CD 117/c-kit, and slightly positive for MS-actin and
SM-actin. The tumor cells were negative for CD 34, S 100,
and only focally positive for vimentin. A ﬁnal conclusion of
an in part cystic degenerated GIST was made of the jejunum
and metastatic nodules on the spleen.
Thepostoperativecoursewascomplicatedbyanobstruc-
tiveileus.Atrelaparotomy,performed10daysaftertheinitial
operation, a tumor was palpated in the horizontal part of
the duodenum. Gastroscopy during the procedure revealed
a polypoid tumor in the distal is duodenum obliterating the
lumen. Duodenal biopsies and lymph node samples were
taken. As the type of surgical interventions is depending on
the histology of the tumor it was decided to wait for the
results of the histopathologic examinations of the biopsies
before additional intervention was performed.
At pathological investigation the biopsies and the abdom-
inal lymphnodes consisted of spindle cells similar to ﬁndings
in the tumor and in the spleen and were diagnosed as GIST
localizations rather than lymph nodes. Five days after the
second operation, when the deﬁnitive histopathology was
known at a gestational age of 17 weeks and 2 days, a third—
now palliative procedure was performed. The horizontal
part of the duodenum was resected over 15cm and a
gastroenterostomy was made Macroscopically, at the stenosis
there were signs of hemorrhage, necrosis, and inﬂammation
in the submucosa. No tumor was seen. Microscopically, a
GIST localisation of 2mm was seen in the submucosa.
After the third operation patient’s condition improved
rapidly. Pregnancy was uncomplicated until week 41 of
gestation, when she developed a mild pregnancy induced
hypertension. No antihypertensive treatment was started.
At 41 weeks and 6 days labour started spontaneously. She
delivered vaginally of a healthy boy, with a weight of 3990gr.
(75percentile)andanApgarscore9/10after1and5minutes,
respectively. The next day the woman and child could return
home in good condition. In a multidisciplinary meeting held
after the delivery it was concluded that no further medical
options would possibly improve maternal outcome. She had
not been enrolled in the phase III imatinib trial [8], open
for entry at the time of diagnosis, due to the absence of
measurable disease after resection of all visible tumor.
Three years after the initial diagnosis she was pregnant
for the second time. Both pregnancy and delivery were
uneventful. At ﬁve years followup she was still in com-
plete remission. On magnetic resonance imaging, repeatedly
performed during this period, no recurrent tumor nor
distant metastases were found. However, one year later, at
a follow-up CT scan, a solid lesion was seen in front of
the horizontal part of the duodenum, with a diameter of
8cm. At laparotomy the tumor with a diameter of 11cm
was removed, but also possible tumor deposition was seen
on the right ovary and the peritoneum. The tumor was
composed of spindle like cells. The mitotic frequency was
20/50HPF. Immunohistochemistry was comparable with a
GIST localization. Microscopy and immunohistochemistry
of lesions suggestive for peritoneal metastasis and metastasis
on the right ovary were also GIST tumor cells. Sequence
analysis showed the typical mutation in Kit exon 11: W557R
(TGG → CGC).
The right ovary was removed 2 months later and also
biopsies were taken from possible tumor residues on the left
ovary. Five small localizations with a maximal diameter of
0.8cm composed of spindle like cells were, with a mitosis
frequency of 20 per 50 high power ﬁeld (HPF), suggestive of
GISTlesionsfoundintherightovary.Immunohistochemical
ﬁndings are comparable to the ﬁndings in the primary
tumor and to the metastic tissue removed during the fourth
operation. CD117 was strong positive, vimentine and CD34
were positive, and MSA and MS-actine were weak positive.
Two months later, 6 years after the ﬁrst surgical proce-
dure, again a paramedian disease recurrence was found by
CT scan. It was now decided to start with imatinib therapy
(400mg1tablet/day)becauseofrecurrentmetastaticdisease.
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starting the imatinib therapy no tumor residue could be
demonstrated (complete radiological response). However, at
the CT scan two cystic lesions were seen at the left ovary,
which were removed in March 2008 during a laparoscopic
partial ovariectomy. The cysts turned out to be a corpus
luteum cyst. Using immunohistochemistry no localization of
GIST could be demonstrated. No other macroscopic tumor
localizations were seen during laparoscopy.
3. Discussion
This case report of a tumorous process diagnosed during
pregnancies stresses the importance of a long-term multi-
disciplinary approach between diﬀerent specialities, includ-
ing obstetrics, surgery, pathology, imaging, and medical
oncology in the treatment of a GIST during pregnancy. It
also shows the course of a long-term survival—even of a
metastaticGISTconsideredtobeofhighrisk—in goodqual-
ity of life. GIST tumours are seldom, especially at younger
ages.Thisexplainsthelimitedexperiencewiththesetumours
diagnosed during pregnancy [6]. In this limited experience
noreferenceismadetothepossibilityofmetastaticdiseasein
the fetus or the developing of GIST in utero. Early diagnosis
andthestartofoptimalmanagementtreatmentaresupposed
to be of importance [3], although our case is illustrating that
even with positive tumour margins and a relative late start
of imatinib long-term survival—more than nine years after
initial—disease is possible. Imatinib was started only when
evaluable metastatic disease occurred, as adjuvant treatment
after (even complete) resection is considered experimental
and should be evaluated in ongoing trials [3]. Our patient
was not included in a trail because she was pregnant.
Gastointestinal stromal tumor (GIST) is the most com-
mon abdominal mesenchymal tumor with an incidence of
approximately 12–14 per million [4, 9]. The incidence of
GIST with a clinical malignant behaviour is estimated 45%
of the total incidence [4]. Compared to other gastroin-
testinal tumors such as colon carcinoma with an incidence
of 30/100000 or gastric carcinoma with an incidence of
16/100000 GIST is a relatively rare neoplasm. GISTs con-
tribute2.2%togastriccancers,13.9%tosmallbowelcancers,
and 0.1% to colorectal cancers [10]. GISTs generally occur
in adults, with a median range between 55 and 65 years
[1, 2]. There are probably no sex diﬀerences in occurrence
[2]. The increased interest on GIST and the consensus on
the diagnostic criteria of GIST has raised the incidence of the
disease [4].
GISTs can develop in the entire gastrointestinal tract and
occasionally in the omentum and mesentery. The stomach
(60–75%) and the small intestine (20–30%) are the most
common localizations of the tumor. GISTs in the esophagus
andcolonarerelativelymorefrequentlyshowingamalignant
behavior [1, 2]. GIST may spread intra-abdominally to the
omentumandperitoneumorreoccurlocallyafternonradical
resection of the primary tumor. Metastasis can be found
in liver and only very rarely in lungs, bones and subcutis
[1, 2]. The spleen involvement as seen in our patient is a rare
ﬁnding [11]. The size of the GISTs may vary from small (1-
2cm) to more than 20cm, as described in our patient [2].
The clinical presentation, such as pain, nausea, vomiting,
bleeding, obstruction, anaemia, melaena depends on the
tumor size and localization. The presentation is nonspeciﬁc
and is therefore of limited use for diagnostic consideration
[2]. A signiﬁcant part of GISTs remains asymptomatic and is
detected incidentally [12]. This is clearly illustrated in our
case, as the patient was free of any symptom, despite the
considerable tumor size and multiple localizations.
In the recent years GIST has been recognized as a
distinct entity, apart from leiomyomas, leiomyoblastomas or
leiomyosarcomas. GIST has been deﬁned as mesenchymal
tumors of the gastrointestinal tract composed of spindle, or
epithelioid, or occasionally pleomorphic cells that frequently
express the c-kit protein, as detected using immunohis-
tochemistry [1]. Immunohistochemical determination has
become the corner stone in the diﬀerential diagnosis of
mesenchymal tumors. The c-kit protein (CD117), a growth
factor receptor for stem cell factor, is positive in approxi-
mately 85–90% of cases. CD34, a hematopoietic progenitor
cell marker normally present on vascular endothelium and a
subset of ﬁbroblast, is positive in 60–70% of GISTs. Smooth
muscle actin (SMA) and muscle speciﬁc actin (MSA) are
expressed in smooth muscle and some myoﬁbroblasts. In
GISTs muscle actins may be present in 20–40% of the cases.
SMA is often reciprocal with CD34 expression. In GISTs S-
100 is positive in 10% of the cases. Heavy caldesmon (HCD),
an actin binding cytoskeleton associated protein, which is
normally present on smooth muscle and myoepithelial cells,
is generally positive in GISTs and smooth muscle tumors.
Vimentin is also generally positive in GISTs [1, 10].
There are no uniform criteria to predict the biological
behavior of GIST. The mitotic rates in combination with
tumor size and tumor site [13] seem to be the most
important prognostic factors. Fletcher has proposed a risk
assessment dividing into four categories:
(1) very low risk (<2cmand<5/50HPF);
(2) low risk (2–5cm and <5/50HPF);
(3) intermediate risk ((a) <5cm and 6–10/50HPF or (b)
5–10cm and <5/50HPF);
(4) high risk ((a) >5cmand>5/50HPF or (b) >10cm
and any mitotic rate or (c) any size and >10/50HPF)
[10].
Localization may also inﬂuence the prognosis. The small
intestinal GIST is associated with the poorest long-term
survival rate, whereas patients with stomach GIST had the
best survival.
In the recent years rapid progress has been made on
the understanding of the oncogenesis of GISTs. The gain-
of-function mutation in the c-kit proto-oncogene, which
can be found in 90% of GISTs, seems to be the basis
of the pathogenesis. This genetic aberration leads to an
unbridled stimulation of c-kit receptor and overexpression
of the tyrosine kinase protein and a subsequent growth
and antiapoptotic behavior of tumor cells [14, 15]. The
introduction of the receptor tyrosine kinase inhibitor STI-
571 (imatinib mesylate or Glivec/Gleevec) heralds a new
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reported in clinical trials on the metastatic disease [8, 16].
Until recently surgery was the only successful treatment
of GISTs. Chemotherapy and radiotherapy had proven to
be ineﬀective. Therefore, only localized disease could be
curatively treated. Because in our case imatinib was not
applicable because of the pregnancy she has been primarily
been operated.
Our case had a remarkable clinical course. Despite
metastatic GIST and the extensive surgical interventions in
the second trimester, the pregnancy had developed unevent-
fully. Furthermore, she was in complete remission in the
ﬁve-year followup. This is highly unexpected in view of the
unfavorable prognosis due to the considerable size (20cm)
and localization of the primary tumor (jejunum), the high
mitotic rate (20/50HPF), and the metastatic presentation
(peritoneum) of the GIST. According to the classiﬁcation by
Fletcher she has to be classiﬁed as a high risk patient (>10cm
and any mitotic rate) [10].
Because she had no measurable disease as evaluated by
repeated CT scans she was not treated with imatinib after the
delivery. Also it is not clear whether imatinib therapy started
earlyinthetreatmentcourseismoreeﬀectivethanatwiththe
moment of more advanced disease it was decided not to start
withthismedication [17]. With recurrenceof disease—more
than 6 years after surgery of the primary tumor—the start
of this medication had a strong eﬀect on the locoregional
metastasis as demonstrated by a complete response at CT
scan and conﬁrmed by laparoscopy more than one year after
start of treatment.
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